MoonLake Immunotherapeutics Announces the Full Dat Datasets from its 24-Week MIRA Clinical Trial, Establishing the Nanobody(R) Sonelokimab as Highly Promanded Therapeutics for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announced positive 24-week top-line results from its global Phase 2 MIRA trial showing that maintenance treatment with its Nanobody(R) sonelokimab led to further improvements in HiSCR75 response rates and other clinically relevant outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS). In June 2023, the MIRA trial met its primary endpoint, the Hidradenitis Suppurativa Clinical Response (HiSCR)75, which is a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials. In June 2023, the MIRA trial met its primary endpoint.

Hidradenitis Suppuriva Clinical Response (HiSC R75, which is a higher measures of clinical response versus the Hi SCR50 measure used in other patients. In June 2023, The MIRA trial met its primary end endpoint, the Hid radenitis Suppurativa Clinical response (HiSCR75, which is a high measure of clinical response versus theHiSCR50 measure used in Other clinical trials. The overall data package created with the MIRA trial establishes MoonLake's position as a leading innovator in the Immunology and Inflammation (I&I) and IL-17 space.